To The Moon
Home
News
TigerAI
Log In
Sign Up
Eyes Closed
+Follow
Posts · 5
Posts · 5
Following · 0
Following · 0
Followers · 0
Followers · 0
Eyes Closed
Eyes Closed
·
2022-02-10
Gains for now...
Sorry, this post has been deleted
看
2.94K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
Eyes Closed
Eyes Closed
·
2022-02-09
$NIO Inc.(NIO)$
Up for now... then nearer to March? I wonder...
看
2.63K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Eyes Closed
Eyes Closed
·
2022-02-08
But for how long will all these truly last...
U.S. funding to now cover study of Novavax's COVID-19 shot in adolescents
Feb 7 (Reuters) - Novavax Inc(said on Monday U.S. government funding for its COVID-19 vaccine had be
U.S. funding to now cover study of Novavax's COVID-19 shot in adolescents
看
3.17K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
Eyes Closed
Eyes Closed
·
2022-01-27
2 days... close it and take profit.
看
2.93K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Eyes Closed
Eyes Closed
·
2022-01-12
$SINGAPORE AIRLINES LTD(C6L.SI)$
In for the long haul
看
4.46K
回复
Comment
点赞
6
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4104823715193190","uuid":"4104823715193190","gmtCreate":1641720646696,"gmtModify":1661494436456,"name":"Eyes Closed","pinyin":"eyesclosedeyesclosed","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/e8cb4318cb1bee321ad47bb2b5ee1403","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":1,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.02.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.29","exceedPercentage":"80.60%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9096765153,"gmtCreate":1644464557490,"gmtModify":1676533930163,"author":{"id":"4104823715193190","authorId":"4104823715193190","name":"Eyes Closed","avatar":"https://community-static.tradeup.com/news/e8cb4318cb1bee321ad47bb2b5ee1403","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4104823715193190","idStr":"4104823715193190"},"themes":[],"htmlText":"Gains for now...","listText":"Gains for now...","text":"Gains for now...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096765153","repostId":"2210563984","repostType":4,"isVote":1,"tweetType":1,"viewCount":2938,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096288059,"gmtCreate":1644399512457,"gmtModify":1676533921178,"author":{"id":"4104823715193190","authorId":"4104823715193190","name":"Eyes Closed","avatar":"https://community-static.tradeup.com/news/e8cb4318cb1bee321ad47bb2b5ee1403","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4104823715193190","idStr":"4104823715193190"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$</a>Up for now... then nearer to March? I wonder...","listText":"<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$</a>Up for now... then nearer to March? I wonder...","text":"$NIO Inc.(NIO)$Up for now... then nearer to March? I wonder...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096288059","isVote":1,"tweetType":1,"viewCount":2632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096363342,"gmtCreate":1644307580680,"gmtModify":1676533910899,"author":{"id":"4104823715193190","authorId":"4104823715193190","name":"Eyes Closed","avatar":"https://community-static.tradeup.com/news/e8cb4318cb1bee321ad47bb2b5ee1403","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4104823715193190","idStr":"4104823715193190"},"themes":[],"htmlText":"But for how long will all these truly last...","listText":"But for how long will all these truly last...","text":"But for how long will all these truly last...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096363342","repostId":"2209905308","repostType":4,"repost":{"id":"2209905308","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1644290884,"share":"https://ttm.financial/m/news/2209905308?lang=en_US&edition=fundamental","pubTime":"2022-02-08 11:28","market":"us","language":"en","title":"U.S. funding to now cover study of Novavax's COVID-19 shot in adolescents","url":"https://stock-news.laohu8.com/highlight/detail?id=2209905308","media":"Reuters","summary":"Feb 7 (Reuters) - Novavax Inc(said on Monday U.S. government funding for its COVID-19 vaccine had be","content":"<html><head></head><body><p>Feb 7 (Reuters) - Novavax Inc(said on Monday U.S. government funding for its COVID-19 vaccine had been expanded to cover a late-stage study in adolescents with a booster component.</p><p>Novavax in July 2020 had received $1.6 billion in funding to develop its protein-based vaccine under a government program aimed at accelerating access to coronavirus vaccines and treatments, formerly called Operation Warp Speed.</p><p>The company late last month filed for emergency use authorization of the vaccine for U.S. adults, a long-awaited step following months of struggles with development and manufacturing problems.</p><p>Novavax's two-dose shot has received authorizations from the European Union and the World Health Organization and was recently cleared for use in adults in Britain and New Zealand.</p><p>Novavax last year started testing its vaccine in adolescents aged 12 to 17.</p><p>Currently, rival Pfizer and its partner BioNTech's COVID-19 vaccine is the only one cleared for individuals in that age group in the United States. The U.S. Food and Drug Administration in January also authorized a booster shot of the companies' vaccine for those 12 years and older.</p><p>Novavax in December said receiving an additional booster dose of its vaccine further increased people's immune response to Omicron. The company cited data from ongoing studies of its vaccine's effectiveness in adolescents and as a booster.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. funding to now cover study of Novavax's COVID-19 shot in adolescents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. funding to now cover study of Novavax's COVID-19 shot in adolescents\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-02-08 11:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Feb 7 (Reuters) - Novavax Inc(said on Monday U.S. government funding for its COVID-19 vaccine had been expanded to cover a late-stage study in adolescents with a booster component.</p><p>Novavax in July 2020 had received $1.6 billion in funding to develop its protein-based vaccine under a government program aimed at accelerating access to coronavirus vaccines and treatments, formerly called Operation Warp Speed.</p><p>The company late last month filed for emergency use authorization of the vaccine for U.S. adults, a long-awaited step following months of struggles with development and manufacturing problems.</p><p>Novavax's two-dose shot has received authorizations from the European Union and the World Health Organization and was recently cleared for use in adults in Britain and New Zealand.</p><p>Novavax last year started testing its vaccine in adolescents aged 12 to 17.</p><p>Currently, rival Pfizer and its partner BioNTech's COVID-19 vaccine is the only one cleared for individuals in that age group in the United States. The U.S. Food and Drug Administration in January also authorized a booster shot of the companies' vaccine for those 12 years and older.</p><p>Novavax in December said receiving an additional booster dose of its vaccine further increased people's immune response to Omicron. The company cited data from ongoing studies of its vaccine's effectiveness in adolescents and as a booster.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2209905308","content_text":"Feb 7 (Reuters) - Novavax Inc(said on Monday U.S. government funding for its COVID-19 vaccine had been expanded to cover a late-stage study in adolescents with a booster component.Novavax in July 2020 had received $1.6 billion in funding to develop its protein-based vaccine under a government program aimed at accelerating access to coronavirus vaccines and treatments, formerly called Operation Warp Speed.The company late last month filed for emergency use authorization of the vaccine for U.S. adults, a long-awaited step following months of struggles with development and manufacturing problems.Novavax's two-dose shot has received authorizations from the European Union and the World Health Organization and was recently cleared for use in adults in Britain and New Zealand.Novavax last year started testing its vaccine in adolescents aged 12 to 17.Currently, rival Pfizer and its partner BioNTech's COVID-19 vaccine is the only one cleared for individuals in that age group in the United States. The U.S. Food and Drug Administration in January also authorized a booster shot of the companies' vaccine for those 12 years and older.Novavax in December said receiving an additional booster dose of its vaccine further increased people's immune response to Omicron. The company cited data from ongoing studies of its vaccine's effectiveness in adolescents and as a booster.","news_type":1,"symbols_score_info":{"NVAX":1}},"isVote":1,"tweetType":1,"viewCount":3165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9099394051,"gmtCreate":1643295200558,"gmtModify":1676533799465,"author":{"id":"4104823715193190","authorId":"4104823715193190","name":"Eyes Closed","avatar":"https://community-static.tradeup.com/news/e8cb4318cb1bee321ad47bb2b5ee1403","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4104823715193190","idStr":"4104823715193190"},"themes":[],"htmlText":"2 days... close it and take profit.","listText":"2 days... close it and take profit.","text":"2 days... close it and take profit.","images":[{"img":"https://static.itradeup.com/news/8941cc8b78ef10f41eb208a750996eb5","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9099394051","isVote":1,"tweetType":1,"viewCount":2931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9002853462,"gmtCreate":1641971665250,"gmtModify":1676533667851,"author":{"id":"4104823715193190","authorId":"4104823715193190","name":"Eyes Closed","avatar":"https://community-static.tradeup.com/news/e8cb4318cb1bee321ad47bb2b5ee1403","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4104823715193190","idStr":"4104823715193190"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>In for the long haul","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>In for the long haul","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$In for the long haul","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002853462","isVote":1,"tweetType":1,"viewCount":4457,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}